ArticleFrontiers in oncology2026
Unmet needs and quality of life burden in chronic myeloid leukemia: results from a nationwide Italian real-world survey.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Optimizing tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia (CML) requires careful consideration of patient quality of life (QoL), which significantly influences treatment adherence and long-term outcomes. Long-term treatment can be associated with persistent symptoms that may negatively impact QoL, adherence, and patient satisfaction. This nationwide Italian survey explored patient experiences, treatment patterns, and factors influencing clinical decision-making in CML, with the aim of better understanding unmet needs and potential barriers to optimal care. Methods: We conducted a cross-sectional survey involving 146 adult patients with CML. A structured questionnaire, developed collaboratively by hematologists and patient association representatives, assessed patient-reported outcomes (PROs), treatment-related burden, and care satisfaction. Analyses were descriptive and exploratory. Results: Despite the availability of effective therapies, a substantial proportion of patients reported impaired QoL due to both disease and treatment-related factors. While most patients reported overall satisfactory QoL, 26% described low or very low QoL. The burden was particularly evident in specific patient subgroups and in later lines of therapy, reflecting a significant physical and psychological impact of CML and its management. Fatigue, weakness, and muscle pain were the most frequently reported symptoms, often persistent and affecting daily functioning. Female patients reported a higher symptom burden and greater psychological distress compared to males. Despite high overall satisfaction with healthcare professionals, relevant unmet needs were identified, particularly regarding information on supportive services, long-term disease management, and fertility-related issues. Treatment-related adverse events were common and frequently chronic, suggesting a substantial cumulative burden over time. Conclusions: Despite the effectiveness of TKIs, patients with CML continue to experience a meaningful and multidimensional burden, particularly in later treatment lines and specific subgroups. These findings highlight the importance of greater attention to patient-centered management in CML, with treatment decisions carefully balancing the benefits and limitations of available therapeutic options to optimize both clinical outcomes and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.